Nanohale AG (ETR:FYB) | WebDisclosure

Basculer en Français

9825	Companies
197283	Keywords
128415	Articles
104954	Press releases

Home
Companies
Nanohale AG

PRESS RELEASE

published on 03/03/2025 at 14:00, 11 months 6 days ago

FYB202/Otulfi® (ustekinumab-aauz), a biosimilar to Stelara®, launched in the United States and the European Union
FYB202/Otulfi® (ustekinumab-aauz), a biosimilar to Stelara®, officially launched in the United States and European Union, offering comparable efficacy and safety. Formycon AG and Fresenius ensure successful market access

Formycon AG Launch Biosimilar Stelara Otulfi
BRIEF

published on 02/25/2025 at 06:35, 11 months 13 days ago

Le FYB203 de Formycon reçoit l'approbation réglementaire britannique

Réglementation Au Royaume-Uni Approbation Des Biosimilaires Formycon FYB203 Traitement Ophtalmique Partenariat Avec Teva
BRIEF

published on 02/25/2025 at 06:35, 11 months 13 days ago

Formycon's FYB203 Receives UK Regulatory Approval

UK Regulatory Biosimilar Approval Formycon FYB203 Ophthalmic Treatment Teva Partnership
PRESS RELEASE

published on 02/25/2025 at 06:30, 11 months 13 days ago

Formycon receives regulatory approval in the UK for FYB203 (aflibercept), a biosimilar to Eylea®, under the brand name AHZANTIVE®
Formycon receives regulatory approval in the UK for FYB203 (aflibercept), a biosimilar to Eylea®, under the brand name AHZANTIVE®. Approval for treating retinal diseases granted by UK's MHRA

Regulatory Approval UK Biosimilar Formycon AHZANTIVE
BRIEF

published on 02/24/2025 at 11:31, 11 months 13 days ago

Formycon AG: Price Target Adjusted Amid Market Pressures

Buy Recommendation Formycon AG Price Pressure Biosimilar Market Investment Reduction
BRIEF

published on 02/24/2025 at 11:31, 11 months 13 days ago

Formycon AG : Objectif de cours ajusté en raison des pressions du marché

Formycon AG Recommandation D'achat Pression Sur Les Prix Réduction Des Investissements Marché Des Biosimilaires
PRESS RELEASE

published on 02/24/2025 at 11:26, 11 months 13 days ago

Original-Research: Formycon AG (von First Berlin Equity Research GmbH): Buy
First Berlin Equity Research updates its research on Formycon AG, maintaining a Buy recommendation with a decreased target price from EUR 82 to EUR 46 due to higher price pressure and reduced investments in biosimilar portfolio

First Berlin Equity Research Buy Recommendation Research Update Formycon AG Biosimilar Portfolio
BRIEF

published on 02/20/2025 at 06:35, 11 months 18 days ago

Formycon Unveils Clinical Data for Ustekinumab Biosimilar FYB202 at ECCO Congress

Formycon AG Regulatory Approval Clinical Data Biosimilar FYB202
BRIEF

published on 02/20/2025 at 06:35, 11 months 18 days ago

Formycon dévoile les données cliniques du biosimilaire d'ustekinumab FYB202 au congrès de l'ECCO

Formycon AG FYB202 Biosimilaire Approbation Réglementaire Données Cliniques
PRESS RELEASE

published on 02/20/2025 at 06:30, 11 months 18 days ago

Formycon presents clinical data on ustekinumab biosimilar FYB202 at the ECCO Congress in Berlin
Formycon presents clinical data on ustekinumab biosimilar FYB202 at ECCO Congress, demonstrating comparability with Stelara. FYB202 approved in multiple regions

Clinical Data ECCO Congress Biosimilar Formycon Ustekinumab

Accesswire

Published on 02/10/2026 at 08:00, 35 minutes ago

Caledonia Mining Corporation Plc - Issue of Securities Pursuant to Long Term Incentive Plan Awards
Published on 02/10/2026 at 01:05, 7 hours 30 minutes ago

Notification of Relevant Change to Significant Shareholder
Published on 02/09/2026 at 23:35, 9 hours ago

Mako Mining Announces Intention to Restructure the Mt. Hamilton Acquisition Consideration and Postponement of Special Meeting of Shareholders to New Meeting Date of March 3, 2026
Published on 02/09/2026 at 23:15, 9 hours 20 minutes ago

IBC Advanced Alloys to Present at the Precious Metals & Critical Minerals Virtual Investor Conference on February 10, 2026
Published on 02/09/2026 at 23:08, 9 hours 27 minutes ago

NV Gold Announces Closing of Non-Brokered Private Placement

View all ACCESSWIRE

EQS Group

Published on 02/10/2026 at 08:00, 35 minutes ago

Transaction in Own Shares
Published on 02/10/2026 at 07:00, 1 hour 35 minutes ago

EQS-Adhoc: ams OSRAM post Q4 above mid-point of guidance, delivers EUR 144 m FCF in FY25 and launches EUR 200 m ‘Simplify’ transformation and savings program
Published on 02/10/2026 at 07:00, 1 hour 35 minutes ago

Waga Energy: Croissance de +23 % des revenus de production de biométhane en 2025
Published on 02/10/2026 at 07:00, 1 hour 35 minutes ago

TUI delivers best Q1 performance with Und. EBIT of €77m, growing strongly by +€26m. We reaffirm our FY26 guidance of +7-10% Und. EBIT growth (at CC), driven by expectations for Summer 2026
Published on 02/10/2026 at 07:00, 1 hour 35 minutes ago

Waga Energy posts a +23% yoy RNG production revenue growth

Les Echos

Published on 02/09/2026 at 18:00, 14 hours 35 minutes ago

LANSON-BCC : Déclaration du nombre total des droits de vote et du nombre d’actions au 31 janvier 2026
Published on 02/09/2026 at 17:45, 14 hours 50 minutes ago

Declaration of voting rights at the end of January 2026
Published on 02/09/2026 at 17:45, 14 hours 50 minutes ago

DAMARTEX / Droits de vote bruts et réels au 31 janvier 2026
Published on 02/09/2026 at 17:45, 14 hours 50 minutes ago

Déclaration des droits de vote à fin janvier 2026
Published on 02/09/2026 at 17:45, 14 hours 50 minutes ago

Déclaration des droits de vote à fin janvier 2026

View all LES ECHOS COMFI WIRE